Drugs & Targets Huge variations between countries in time for reimbursement decisions on new cancer drugs October 19, 2018Vol.44 No.39
Drugs & Targets AbbVie’s sNDA accepted for priority review for Imbruvica in combination with Gazyva for previously untreated CLL October 19, 2018Vol.44 No.39
Drugs & Targets The Parker Institute, Xyphos Biosciences developing universal programmable CAR-T cells October 19, 2018Vol.44 No.39
Drugs & Targets PanTher Therapeutics, MD Anderson collaborate on pancreatic cancer treatment October 19, 2018Vol.44 No.39
Drugs & Targets Myriad, Pfizer announce commercialization plan for talazoparib companion diagnostic October 12, 2018Vol.44 No.38
Drugs & Targets Foundation Medicine introduces liquid biopsy for solid tumors in patients with advanced cancer October 12, 2018Vol.44 No.38
Drugs & Targets Celyad announces agreement for Horizon Discovery’s shRNA platform to develop next- gen allogeneic CAR-T therapies October 12, 2018Vol.44 No.38
Drugs & Targets Novitas Solutions approves coverage of UPMC-developed test for diagnosis of thyroid nodules October 12, 2018Vol.44 No.38
